SCHEMBL275909

SCHEMBL275909

OC(c1ccc(-c2ccccc2)cc1)c1ccccc1C(O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA9 Q16790 2/20 0.50
MEN1 O00255 1/20 0.50
MAPT P10636 1/20 0.50
CYP2C9 P11712 1/20 0.50
KMT2A Q03164 1/20 0.50
CA12 O43570 1/20 0.48
CA14 Q9ULX7 1/20 0.48
ACP3 P15309 2/20 0.47
PTGS2 P35354 1/20 0.47
CHRNB2 P17787 1/20 0.45
CHRNA4 P43681 1/20 0.45
MMP3 P08254 1/20 0.44
BCL2L1 Q07817 1/20 0.44
ALDH1A1 P00352 1/20 0.43
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3585861 0.87 CA12 (0.59) CA1CA2CA9CA12CA14
SCHEMBL29048107 0.87 CA1 (0.49) CA1CA2CA9MEN1MAPT
SCHEMBL29141204 0.86 CA1 (0.69) CA1CA2CA9MEN1MAPT
SCHEMBL11641801 0.86 ESR2 (0.46) CA1CA2CA9MEN1MAPT
SCHEMBL4504963 0.85 CA1 (0.62) CA1CA2CA9CA12CA14
SCHEMBL7809671 0.85 MEN1 (0.63) MEN1MAPTCYP2C9KMT2A
SCHEMBL8925746 0.82 CA1 (0.64) CA1CA2CA9CA12CA14
SCHEMBL29860944 0.82 CA1 (0.64) CA1CA2CA9CA12CA14
SCHEMBL3278303 0.77 KMT2A (0.47) CA1CA2CA9MEN1MAPT
SCHEMBL11642923 0.77 ALDH1A1 (0.65) CA1CA2CA9CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134035-B2 Preparation of asymmetric anthracene derivatives and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2012-03-13 US disclosed
US-8134035-B2 Preparation of asymmetric anthracene derivatives and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2012-03-13 US disclosed
US-20110065924-A1 PREPARATION OF ASYMMETRIC ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME DOOSAN CORPORATION (KR) 2011-03-17 US disclosed
US-20110065924-A1 PREPARATION OF ASYMMETRIC ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME DOOSAN CORPORATION (KR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065924-A1 PREPARATION OF ASYMMETRIC ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME AKR7A2, ACMSD, ALKBH3 CA1 2979/4885CA2 1850/4885CA9 1667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.